Contemporary approaches for imaging skeletal metastasis

Bone Research

Volumn 3, Issue 1, 2015, Pages

  Ulmert, David ^a,b   Solnes, Lilja ^c   Thorek, Daniel LJ ^c,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84969976124     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/BONERES.2015.24     Document Type: Review

References (105)

1. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–124.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655–1664.
4. Stenbygaard LE, Sørensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung – a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol 1997; 36: 301–306.
5. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57: 229–232.
6. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193–201.
7. Hindié E, Zanotti-Fregonara P, Keller I et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007; 14: 799–807.
8. Li S, Peng Y, Weinhandl ED et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol 2012; 4: 87–93.
9. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.
10. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989–2994.
11. Sathiakumar N, Delzell E, Morrisey MA et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14: 177–183.
12. Manders K, van de Poll-Franse LV, Creemers GJ et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 2006; 6: 179.
13. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892–2899.
14. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998; 77: 336– 340.
15. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162–167.
16. Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948–957.
17. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274–284.
18. 99 (molybdate) as tracer. J Lab Clin Med 1963; 62: 330–340.
19. 99mTc: an approach to the medical isotope crisis. J Nucl Med 2010; 51: 13N–16N.
20. 99mTc-Methyl diphosphonate. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information, 2004.
21. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75–85.
22. 99mTc-labeled methylene diphosphonate. J Orthop Res 1984; 1: 236–243.
23. Lavender JP, Khan RA, Hughes SP. Blood flow and tracer uptake in normal and abnormal canine bone: comparisons with Sr-85 microspheres, Kr-81m, and Tc-99m MDP. J Nucl Med 1979; 20: 413–418.
24. Sagar VV, Piccone JM, Charkes ND. Studies of skeletal tracer kinetics. III. Tc-99m(Sn)methylenediphosphonate uptake in the canine tibia as a function of blood flow. J Nucl Med 1979; 20: 1257–1261.
25. Einhorn TA, Vigorita VJ, Aaron A. Localization of technetium-99m methylene diphosphonate in bone using microautoradiography. J Orthop Res 1986; 4: 180–187.
26. Ogawa K, Saji H. Advances in drug design of radiometal-based imaging agents for bone disorders. Int J Mol Imaging 2011; 2011: 537687.
27. 99mTc-MDP. Invest Radiol 1983; 18: 470–478.
28. Elmaleh DR, Hnatowitch DJ, Cochavi S, McKusick KA, Brownell GL, Strauss WH. Emission tomographic images of the skull with fluorine-18. Int J Nucl Med Biol 1980; 7: 289–293.
29. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371–388.
30. Schirrmeister H, Guhlmann A, Elsner K et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40: 1623–1629.
31. 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. JNucl Med 2006; 47: 287–297.
32. Satyamurthy N, Amarasekera B, Alvord CW, Barrio JR, Phelps ME. Tantalum [18O]water target for the production of [18F]fluoride with high reactivity for the preparation of 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 2002; 4: 65–70.
33. Garcia-Torano E, Medina VP, Ibarra MR. The half-life of 18F. Appl Radiat Isot 2010; 68: 1561–1565; discussion 1565.
34. Win AZ, Aparici CM. Factors affecting uptake of NaF-18 by the normal skeleton. J Clin Med Res 2014; 6: 435–442.
35. Piert M, Zittel TT, Becker GA et al. Assessment of porcine bone metabolism by dynamic. J Nucl Med 2001; 42: 1091–1100.
36. Wootton R, Dore C. The single-passage extraction of 18F in rabbit bone. Clin Phys Physiol Meas 1986; 7: 333–343.
37. Frost ML, Blake GM, Cook GJ, Marsden PK, Fogelman I. Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: (18)F-fluoride PET study of treatment-naive and treated postmenopausal women. Bone 2009; 45: 942–948.
38. Grynpas MD. Fluoride effects on bone crystals. J Bone Miner Res 1990; 5: S169–S175.
39. Hawkins RA, Choi Y, Huang SC et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992; 33: 633–642.
40. Tomlinson RE, Shoghi KI, Silva MJ. Nitric oxide-mediated vasodilation increases blood flow during the early stages of stress fracture healing. J Appl Physiol 1985 2014; 116: 416–424.
41. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics 2003; 23: 341–358.
42. Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Magnetic resonance imaging of the normal bone marrow. Skeletal Radiol 1998; 27: 471–483.
43. Lecouvet FE, Geukens D, Stainier A et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25: 3281–3287.
44. Venkitaraman R, Cook GJ, Dearnaley DP et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 2009; 53: 241–247.
45. 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med 2013; 38: e290–e296.
46. Warburg O. On the origin of cancer cells. Science 1956; 123: 309–314.
47. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.
48. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519–530.
49. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765–770.
50. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009; 65: 333–338.
51. Ota N, Kato K, Iwano S et al. Comparison of (1)(8)F-fluoride PET/CT, (1)(8)F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol 2014; 87: 20130444.
52. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375–3379.
53. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751–756.
54. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20: 2189–2192.
55. Katayama T, Kubota K, Machida Y, Toriihara A, Shibuya H. Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Ann Nucl Med 2012; 26: 426–435
56. Simoncic U, Perlman S, Liu G, Staab MJ, Straus JE, Jeraj R. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 2015; 13: e7–e17.
57. Morris MJ, Akhurst T, Larson SM et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11: 3210–3216.
58. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J Nucl Med 2011; 52: 81–89.
59. Lebtahi R, Cadiot G, Delahaye N et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999; 40: 1602–1608.
60. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 2014; 4: 426–434.
61. Osborne JR, Green DA, Spratt DE et al. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol 2014; 191: 1439–1445.
62. Szabo Z, Mena E, Rowe SP et al. Initial evaluation of [F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015 Apr 21. [Epub ahead of print]
63. Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486–495.
64. Perik PJ, Lub-De Hooge MN, Gietema JA et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. JClinOncol2006; 24: 2276–2282.
65. Brouwers AH, Dorr U, Lang O et al. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 2002; 23: 229–236.
66. Brouwers AH, Buijs WC, Oosterwijk E et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 2003; 9: 3953S–3960S.
67. Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. J Nucl Med 2014; 55: 525–528.
68. O’Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008; 9: 766–776.
69. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS 2010; 5: 463–466.
70. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.
71. Imbriaco M, Larson SM, Yeung HW et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 1998; 4: 1765–1772.
72. Wakabayashi H, Nakajima K, Mizokami A et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med 2013; 27: 802–807.
73. Ulmert D, Kaboteh R, Fox JJ et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 2012; 62: 78–84.
74. Pierce TP, Jauregui JJ, Cherian JJ, Elmallah RK, Mont MA. Imaging evaluation of patients with osteonecrosis of the femoral head. Curr Rev Musculoskelet Med 2015 Jun 5. [Epub ahead of print]
75. Maas O, Joseph GB, Sommer G, Wild D, Kretzschmar M. Association between cartilage degeneration and subchondral bone remodeling in patients with knee osteoarthritis comparing MRI and Tc-DPD-SPECT/ CT. Osteoarthritis Cartilage 2015 May 29. doi: 10.1016/j.joca.2015.05.014. [Epub ahead of print]
76. Ha S, Hong SH, Paeng JC et al. Comparison of SPECT/CT and MRI in diagnosing symptomatic lesions in ankle and foot pain patients: diagnostic performance and relation to lesion type. PLoS One 2015; 10: e0117583.
77. Segall G, Delbeke D, Stabin MG et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. JNuclMed2010; 51: 1813–1820.
78. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007; 45: 669–676, vi.
79. Muzahir S, Jeraj R, Liu G et al. Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18) F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging 2015; 5: 162–168.
80. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123–1128.
81. Rossleigh MA, Lovegrove FT, Reynolds PM, Byrne MJ, Whitney BP. The assessment of response to therapy of bone metastases in breast cancer. Aust N Z J Med 1984; 14: 19–22.
82. van Schelven WD, Pauwels EK. The flare phenomenon: far from fair and square. Eur J Nucl Med 1994; 21: 377–380.
83. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984; 142: 773–776.
84. McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer 2015; 15: 371.
85. Cook GJ, Venkitaraman R, Sohaib AS et al. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging 2011; 38: 7–13.
86. Schneider JA, Divgi CR, Scott AM et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994; 35: 1748–1752.
87. Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med 2009; 34: 346–349.
88. Gillespie PJ, Alexander JL, Edelstyn GA. Changes in 87mSr concentrac-tions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer. J Nucl Med 1975; 16: 191–193.
89. Sugawara Y, Kajihara M, Semba T, Ochi T, Fujii T, Mochizuki T. Healing focal ‘‘flare’’ phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med 2005; 30: 672–673.
90. Cheng TH, Holman BL. Increased skeletal:renal uptake ratio: etiology and characteristics. Radiology 1980; 136: 455–459.
91. Swislocki AL, Barnett CA, Darnell P, Noth RH. Hyperthyroidism: an underappreciated cause of diffuse bone disease. Clin Nucl Med 1998; 23: 241–243.
92. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006; 79: 32–36.
93. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–1159.
94. Lee RJ, Saylor PJ, Michaelson MD et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013; 19: 3088–3094.
95. Fay AP, Albiges L, Bellmunt J. Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 2015; 15: 151–156.
96. Doran MG, Spratt DE, Wongvipat J et al. Cabozantinib resolves bone scans in tumor-naive mice harboring skeletal injuries. Mol Imaging 2014; 13. doi: 10.2310/7290.2014.00026.
97. Gentili A, Miron SD, Bellon EM. Nonosseous accumulation of bone-seeking radiopharmaceuticals. Radiographics 1990; 10: 871–881.
98. Cerci SS, Suslu H, Cerci C et al. Different findings in Tc-99m MDP bone scintigraphy of patients with sickle cell disease: report of three cases. Ann Nucl Med 2007; 21: 311–314.
99. Loutfi I, Collier BD, Mohammed AM. Nonosseous abnormalities on bone scans. J Nucl Med Technol 2003; 31: 149–153; quiz 154–146.
100. Zhang H, Huang R, Cheung NK et al. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 2014; 20: 2182–2191.
101. Beekman FJ, van der Have F, Vastenhouw B et al. U-SPECT-I: a novel system for submillimeter-resolution tomography with radiolabeled molecules in mice. J Nucl Med 2005; 46: 1194–1200.
102. Beekman F, van der Have F. The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur J Nucl Med Mol Imaging 2007; 34: 151–161.
103. Torigian DA, Zaidi H, Kwee TC et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology 2013; 267: 26–44.
104. Hofmann M, Pichler B, Scholkopf B, Beyer T. Towards quantitative PET/ MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 2009; 36: S93–S104.
105. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol 2014; 83: 84–94.